A Philadelphia transportation company filed a lawsuit against pharmaceutical conglomerate Gilead for what it claims are “exorbitant” drug prices.
According to reports, the Southeastern Pennsylvania Transportation Authority claims Gilead abused its patent monopoly on the Sovaldi drug, which treats Hepatitis C. The suit, filed Tuesday, argues that the $1,000 cost for a single pill is the result of Gilead’s “limited rights as a patent holder,” which “do not translate into a license to price gouge consumers.”
The transportation authority says it has spent more than $2.4 million on Sovaldi for its employees. The company is now seeking to represent a nationwide class in legal action against Gilead.
The SPTA is seeking an unspecified amount of money damages, according to reports.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI